MX2021004600A - Forma cristalina del inhibidor de maleato de tirosina quinasa y metodo de preparacion para el mismo. - Google Patents

Forma cristalina del inhibidor de maleato de tirosina quinasa y metodo de preparacion para el mismo.

Info

Publication number
MX2021004600A
MX2021004600A MX2021004600A MX2021004600A MX2021004600A MX 2021004600 A MX2021004600 A MX 2021004600A MX 2021004600 A MX2021004600 A MX 2021004600A MX 2021004600 A MX2021004600 A MX 2021004600A MX 2021004600 A MX2021004600 A MX 2021004600A
Authority
MX
Mexico
Prior art keywords
crystal form
preparation
method therefor
maleate
tyrosine kinase
Prior art date
Application number
MX2021004600A
Other languages
English (en)
Inventor
Zhenxing Du
Zhenjun Qiu
Quanliang Zhang
Yongxing Cao
Yahui Ma
Junran Yang
Yanli Wei
Jie Wang
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2021004600A publication Critical patent/MX2021004600A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan una forma cristalina de un maleato de un inhibidor de tirosina quinasa y un método de preparación para el mismo; específicamente, se proporcionan una forma cristalina I, una forma cristalina II, una forma cristalina III, una forma cristalina IV y una forma cristalina V del compuesto como se muestra en la fórmula (I) y un método de preparación para el mismo; la nueva forma cristalina tiene una buena estabilidad, por lo que es mejor utilizarla en tratamientos clínicos. (ver Fórmula).
MX2021004600A 2018-10-22 2019-10-21 Forma cristalina del inhibidor de maleato de tirosina quinasa y metodo de preparacion para el mismo. MX2021004600A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201811231321 2018-10-22
PCT/CN2019/112216 WO2020083188A1 (zh) 2018-10-22 2019-10-21 一种酪氨酸激酶抑制剂的一马来酸盐的晶型及其制备方法

Publications (1)

Publication Number Publication Date
MX2021004600A true MX2021004600A (es) 2021-06-15

Family

ID=70330660

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004600A MX2021004600A (es) 2018-10-22 2019-10-21 Forma cristalina del inhibidor de maleato de tirosina quinasa y metodo de preparacion para el mismo.

Country Status (12)

Country Link
US (1) US20210355109A1 (es)
EP (1) EP3872072A4 (es)
JP (1) JP2022508864A (es)
KR (1) KR20210081367A (es)
CN (1) CN112566904A (es)
AU (1) AU2019365166A1 (es)
BR (1) BR112021007477A2 (es)
CA (1) CA3115872A1 (es)
MX (1) MX2021004600A (es)
TW (2) TWI762825B (es)
WO (1) WO2020083188A1 (es)
ZA (1) ZA202103278B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021037185A1 (zh) * 2019-08-30 2021-03-04 江苏恒瑞医药股份有限公司 一种低杂质含量的酪氨酸激酶抑制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102020639A (zh) 2009-09-14 2011-04-20 上海恒瑞医药有限公司 6-氨基喹唑啉或3-氰基喹啉类衍生物、其制备方法及其在医药上的应用
CN102675287A (zh) * 2011-03-11 2012-09-19 江苏恒瑞医药股份有限公司 (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用
CN103539783A (zh) 2012-07-12 2014-01-29 江苏恒瑞医药股份有限公司 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法
CN105367552A (zh) * 2015-01-09 2016-03-02 苏州晶云药物科技有限公司 来那替尼马来酸盐的新晶型及其制备方法
CN107793399A (zh) * 2016-09-07 2018-03-13 上海翰森生物医药科技有限公司 Cdk4/6抑制剂及其制备方法和应用

Also Published As

Publication number Publication date
CN112566904A (zh) 2021-03-26
EP3872072A4 (en) 2022-07-13
BR112021007477A2 (pt) 2021-07-27
TWI762825B (zh) 2022-05-01
WO2020083188A1 (zh) 2020-04-30
CA3115872A1 (en) 2020-04-30
US20210355109A1 (en) 2021-11-18
TWI770934B (zh) 2022-07-11
KR20210081367A (ko) 2021-07-01
TW202030186A (zh) 2020-08-16
AU2019365166A1 (en) 2021-06-03
EP3872072A1 (en) 2021-09-01
TW202130629A (zh) 2021-08-16
ZA202103278B (en) 2022-08-31
JP2022508864A (ja) 2022-01-19

Similar Documents

Publication Publication Date Title
PH12015502284B1 (en) Protein kinase inhibitors
MX2022006609A (es) Compuesto de quinazolina que contiene anillo espiro.
MX2013010444A (es) Superar la resistencia a inhibidores de la via erbb.
MX2014004307A (es) Inhibidores de proteinas quinasas.
MY188447A (en) Indazole compounds as fger kinase inhibitor, preparation and use thereof
UA100540C2 (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
EA201000093A1 (ru) Производные пиридазинона
JO3794B1 (ar) المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
EA201100966A1 (ru) Производные пиридазинона
MX2012002876A (es) Derivados de dihidropteridinona, proceso para su preparacion y uso farmaceutico.
EA024194B8 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
EA201201081A1 (ru) Производные гетарил[1,8]нафтиридина
EA201201170A1 (ru) Гетариламинонафтиридины
PH12019500681A1 (en) Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof
EA201001648A1 (ru) Производные пиридазинона
EP4249071A3 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
UA108878C2 (ru) Ингибиторы протеинтирозинкиназной активности
JO3793B1 (ar) مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
MX2022000199A (es) Compuesto de pirazolona y pirimidina, y metodo de preparacion y uso del mismo.
MX359069B (es) Sal y formas cristalinas de inhibidor de quinasa tipo polo-4.
MX2012007896A (es) Derivados de piridino-piridinonas arilsulfonamidas, su preparacion y su uso en terapeutica.
EA201101041A1 (ru) Производные пиридазинона
MX2021004600A (es) Forma cristalina del inhibidor de maleato de tirosina quinasa y metodo de preparacion para el mismo.
MX2022005201A (es) Formulaciones de naftalimida dimerica.
WO2015114638A3 (en) Use of casein kinase i inhibitors for depleting stem cells